Drug combination before surgery for mucosal melanoma
Part of Cancer, Skin clinical trials.
This trial tests whether giving two drugs (SHR-1701 and famitinib) before surgery, followed by additional treatment based on how well the tumor responds, can help patients with mucosal melanoma (a rare skin cancer in moist areas like the mouth or nose). The goal is to shrink the tumor and improve outcomes after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Confirmed mucosal melanoma (biopsy-proven cancer in mouth, nose, or other moist areas)
- Cancer is resectable (doctors believe it can be completely removed with surgery)
- Good overall health (ECOG performance status 0 or 1: able to do daily activities with minimal limitations)
- Life expectancy of at least 12 weeks
- No prior treatment with PD-1/PD-L1 inhibitors or anti-angiogenic drugs
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three immunotherapy drugs (cemiplimab, fianlimab, and ipilimumab) before surgery in people with melanoma that can be surgically removed. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
This trial tests two experimental drugs, AK104 or AK112, combined with a targeted therapy called axitinib for people with metastatic mucosal melanoma (a rare type of skin cancer that has spread). The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This Phase 2 trial tests three medicines given before surgery for people with high-risk acral melanoma (a skin cancer type). It aims to shrink or control the cancer earlier and see how well the treatment works and is tolerated.
This trial tests two immunotherapy drugs, ipilimumab and nivolumab, given before surgery for people whose melanoma has come back after previous anti-PD1 treatment. The goal is to see if this combination can shrink the tumor and help prevent future recurrence.
This trial tests a combination of chemo drugs (paclitaxel polymersomes, carboplatin) and an immunotherapy (adebelimab) before surgery for people with mucosal melanoma that can be removed. The goal is to see if this treatment shrinks the tumor and improves outcomes.
This trial tests a combination of three drugs (pucotenlimab, lenvatinib, and temozolomide) given before surgery to shrink head and neck mucosal melanoma and improve outcomes. It is for people whose cancer can be surgically removed.
Hear when a new Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.